Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy

Research output: Contribution to journalArticlepeer-review

Abstract

Pharmacogenetics could be a useful tool for performing tailored anticancer chemotherapy. Several polymorphisms potentially affecting enzymes responsible for metabolism, transport and mechanism of action of irinotecan, fluoropyrimidines and antifolate agents have been investigated and sometimes associated with toxicity and response. In particular, uridine diphosphoglucuronosyl transferase 1A1 (UGT1A1) enzyme is responsible for detoxification of irinotecan active metabolite, SN38. A polymorphic structure in the promoter region (UGT1A1*28) may affect irinotecan toxicity and SN38 plasma level. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the folate cycle, presenting two common polymorphisms (677C>T and 1298 A>C) which have impact on toxicity and efficacy of methotrexate and 5-fluorouracil.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 4
Publication statusPublished - Nov 2004

Keywords

  • 5-fluorouracil
  • Irinotecan
  • Methotrexate
  • MTHFR
  • Pharmacogenetics
  • UGT1A1

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy'. Together they form a unique fingerprint.

Cite this